by The Global Non Opioid Pain Treatment Market is witnessing high growth owing to rising prevalence of chronic pains including osteoarthritis, musculoskeletal conditions, neuropathic pain and cancer pain. Non-opioid drugs such as acetaminophen, NSAIDs and anticonvulsants are widely used for treatment of mild to moderate pain. They offer advantages like minimal side effects, effectiveness against chronic pain and safety of use in elderly population. The need for safer pain management alternatives amid growing opioid abuse has boosted adoption of non-opioid therapies.
The Global Non Opioid Pain Treatment Market is estimated to be valued at US$ 43.67 Bn in 2024 and is expected to exhibit a CAGR of 8.1% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the Global Non Opioid Pain Treatment are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd. , Sun Pharmaceutical Industries Ltd. , Cipla Inc. , Fresenius Kabi AG , GSK, Vertex Pharmaceuticals Incorporated, Pacira BioSciences, Collegium Pharmaceuticals, Cara Therapeutics, Akelos, Fidia Farmaceutici S.p.A. , Sanofi , Eli Lilly and Company, Merck Co, Acorda Therapeutics, Hyloris Pharmaceuticals, Hikma Pharmaceuticals PLC. The key players are focused on developing advanced therapeutics and expanding their product portfolios through acquisitions and approvals.
The key opportunities in the Global Non Opioid Pain Treatment Market Challenges And Opportunities include increasing investments by governments and pharma companies in R&D of novel drugs, growing awareness about alternatives to opioid drugs among patients and physicians, and rising focus on management of chronic pain. Moreover, favorable regulations and reimbursement policies are further augmenting adoption of non-opioid therapies across regions.
The Global Non Opioid Pain Treatment Market Trends is witnessing high growth across regions including North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. Significant patient population, advanced healthcare infrastructure, and high affordability are supporting expansion of non-opioid drugs in developed regions. Meanwhile, improving access to healthcare and focus on pain management are fueling market growth in developing economies.
Market Drivers
The primary driver for the Global Non Opioid Pain Treatment Market is the rising prevalence of chronic pain disorders associated with aging population and sedentary lifestyles. It is estimated that approximately one-third of global population suffers from chronic pain. Moreover, growing awareness and focus on addressing the opioid overdose epidemic is prompting patients and physicians to adopt safer alternatives like non-opioid therapies. Stringent regulations on opioid prescribing practices and innovations in non-opioid drug delivery are further propelling the market growth.
PEST Analysis
Political: Regulations around opioid usage have become stricter. Governments across regions are pushing for development and usage of alternative non-opioid therapies to curb addiction issues.
Economic: High healthcare costs associated with opioid addiction treatments are driving focus onto safer non-opioid alternatives. Rise in disposable incomes is increasing spend on chronic pain management.
Social: Growing awareness about dangers of long term opioid usage and addiction is increasing patient preference for non-opioid therapies. Ageing population struggling more with chronic pain conditions also drives demand.
Technological: Advancements in drug delivery mechanisms, newer molecular targets and formulation research have enabled development of novel non-opioid therapeutics with improved efficacy and fewer side effects. Computer aided drug discovery tools are expediting the R&D process.
The North American region accounts for the largest share of the global non-opioid pain treatment market currently, in terms of value. This is owing to the presence of major pharmaceutical companies developing innovative therapies, rising incidences of chronic pain conditions, and supportive regulatory environment driving new product approvals.
The Asia Pacific region is poised to be the fastest growing market for non-opioid pain treatment over the forecast period. Factors such as the large patient pool suffering from muscoskeletal disorders, growing geriatric population, increasing healthcare investments and expanding pharmaceutical industry in the region are expected to primarily drive the high growth witnessed
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it
Alice Mutum
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.LinkedIn
